3,135 research outputs found
Isabelle/PIDE as Platform for Educational Tools
The Isabelle/PIDE platform addresses the question whether proof assistants of
the LCF family are suitable as technological basis for educational tools. The
traditionally strong logical foundations of systems like HOL, Coq, or Isabelle
have so far been counter-balanced by somewhat inaccessible interaction via the
TTY (or minor variations like the well-known Proof General / Emacs interface).
Thus the fundamental question of math education tools with fully-formal
background theories has often been answered negatively due to accidental
weaknesses of existing proof engines.
The idea of "PIDE" (which means "Prover IDE") is to integrate existing
provers like Isabelle into a larger environment, that facilitates access by
end-users and other tools. We use Scala to expose the proof engine in ML to the
JVM world, where many user-interfaces, editor frameworks, and educational tools
already exist. This shall ultimately lead to combined mathematical assistants,
where the logical engine is in the background, without obstructing the view on
applications of formal methods, formalized mathematics, and math education in
particular.Comment: In Proceedings THedu'11, arXiv:1202.453
BioDiVinE: A Framework for Parallel Analysis of Biological Models
In this paper a novel tool BioDiVinEfor parallel analysis of biological
models is presented. The tool allows analysis of biological models specified in
terms of a set of chemical reactions. Chemical reactions are transformed into a
system of multi-affine differential equations. BioDiVinE employs techniques for
finite discrete abstraction of the continuous state space. At that level,
parallel analysis algorithms based on model checking are provided. In the
paper, the key tool features are described and their application is
demonstrated by means of a case study
Measurement of the properties of the Ξb∗ 0 baryon
We perform a search for near-threshold Ξb0 resonances decaying to Ξb−π+ in a sample of proton-proton collision data corresponding to an integrated luminosity of 3 fb−1 collected by the LHCb experiment. We observe one resonant state, with the following properties: mΞb∗0−mΞb−−mπ+=15.727±0.068stat±0.023systMeV/c2ΓΞb∗0=0.90±0.16stat±0.08systMeV.This confirms the previous observation by the CMS collaboration. The state is consistent with the JP = 3/2+ Ξb∗ 0 resonance expected in the quark model. This is the most precise determination of the mass and the first measurement of the natural width of this state. We have also measured the ratio σpp→Ξb∗0XℬΞb∗0→Ξb−π+σpp→Ξb−X=0.28±0.03stat.±0.01syst.
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
Contains fulltext :
208854.pdf (publisher's version ) (Open Access)It has been estimated by the World Health Organization (WHO) that over 71 million people were infected with the hepatitis C virus (HCV) in 2015. Since then, a number of highly effective direct-acting antiviral (DAA) regimens have been licensed for the treatment of chronic HCV infection: sofosbuvir/daclatasvir, sofosbuvir/ledipasvir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir. With these treatment regimens, almost all chronic HCV-infected patients, even including prior DAA failures, can be treated effectively and safely. It is therefore likely that further development of DAAs will be limited. In this descriptive review we provide an overview of the clinical pharmacokinetic characteristics of currently available DAAs by describing their absorption, distribution, metabolism, and excretion. Potential drug-drug interactions with the DAAs are briefly discussed. Furthermore, we summarize what is known about the pharmacodynamics of the DAAs in terms of efficacy and safety. We briefly discuss the relationship between the pharmacokinetics of the DAAs and efficacy or toxicity in special populations, such as hard to cure patients and patients with liver cirrhosis, liver transplantation, renal impairment, hepatitis B virus or HIV co-infection, bleeding disorders, and children. The aim of this overview is to educate/update prescribers and pharmacists so that they are able to safely and effectively treat HCV-infected patients even in the presence of underlying co-infections or co-morbidities
- …